CD22 and acute lymphoblastic leukemia: This work retrospectively analyzes the experience of the use of siltuximab in the management of CRS after two CAR T-cell therapies: tisagenlecleucel and tandem CD19/CD22, the latter as a compassionate use therapy in a cohort of children and AYA diagnosed with r/r B-ALL.